Peter Wolfe - 12 Dec 2022 Form 4 Insider Report for ZyVersa Therapeutics, Inc. (ZVSA)

Role
Chief Financial Officer
Signature
/s/ Peter Wolfe
Issuer symbol
ZVSA
Transactions as of
12 Dec 2022
Net transactions value
$0
Form type
4
Filing time
14 Dec 2022, 18:37:39 UTC
Next filing
20 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZVSA Common Stock Award +41,585 41,585 12 Dec 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZVSA Stock Options (right to buy) Award $0 +9,927 $0.000000 9,927 12 Dec 2022 Common Stock 9,927 $5.09 Direct F2
transaction ZVSA Stock Options (right to buy) Award $0 +9,927 $0.000000 9,927 12 Dec 2022 Common Stock 9,927 $5.09 Direct F3
transaction ZVSA Stock Options (right to buy) Award $0 +39,708 $0.000000 39,708 12 Dec 2022 Common Stock 39,708 $11.58 Direct F4
transaction ZVSA Stock Options (right to buy) Award $0 +21,840 $0.000000 21,840 12 Dec 2022 Common Stock 21,840 $16.36 Direct F5
transaction ZVSA Stock Options (right to buy) Award $0 +21,840 $0.000000 21,840 12 Dec 2022 Common Stock 21,840 $16.36 Direct F6
transaction ZVSA Warrant (right to buy) Award $0 +18,058 $0.000000 18,058 12 Dec 2022 Common Stock 18,058 $6.90 Direct F7
transaction ZVSA Warrant (right to buy) Award $0 +11,763 $0.000000 11,763 12 Dec 2022 Common Stock 11,763 $11.58 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.
F2 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on October 21, 2016.
F3 100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017.
F4 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020.
F5 The option vests in 3 equal annual installments commencing on February 8, 2022.
F6 The option vests in 3 equal annual installments commencing on January 28, 2023.
F7 The warrant is immediately exercisable in full.